Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler K R, Ceballos-Baumann A O, Ohly A, Oertel W, Künig G
Department of Neurology, University of Berlin, Germany.
J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13-7. doi: 10.1136/jnnp.64.1.13.
Botulinum toxin injections have become a first line therapeutic approach in cervical dystonia. Nevertheless, published dosing schedules, responder rates, and frequency of adverse events vary widely. The present prospective multicentre placebo controlled double blind dose ranging study was performed in a homogenous group of previously untreated patients with rotational torticollis to obtain objective data on dose-response relations.
Seventy five patients were randomly assigned to receive treatment with placebo or total doses of 250, 500, and 1000 Dysport units divided between one splenius capitis (0, 175, 350, 700 units) and the contralateral sternocleidomastoid (0, 75, 150, 300 units) muscle. Assessments were obtained at baseline and weeks 2, 4, and 8 after treatment and comprised a modified Tsui scale, a four point pain scale, a checklist of adverse events, global assessment of improvement, and a global rating taking into account efficacy and adverse events. At week 8 the need for retreatment was assessed and then the code was unblinded. For those still responding, there was an open follow up until retreatment to assess the duration of effect.
Seventy nine per cent reported subjective improvement at one or more follow up visits. Decreases in the modified Tsui score were significant at week 4 for the 500 and 1000 unit groups versus placebo (p<0.05). Additionally positive dose-response relations were found for the degree of subjective improvement, duration of improvement, improvement on clinical global rating, and need for reinjection at eight weeks. A significant dose relation was also established for the number of adverse events overall and for the incidence of neck muscle weakness and voice changes.
Magnitude and duration of improvement was greatest after injections of 1000 units Dysport; however, at the cost of significantly more adverse events. Therefore a lower starting dose of 500 units Dysport is recommended in patients with cervical dystonia, with upward titration at subsequent injection sessions if clinically necessary.
肉毒杆菌毒素注射已成为颈部肌张力障碍的一线治疗方法。然而,已公布的给药方案、有效率和不良事件发生率差异很大。本前瞻性多中心安慰剂对照双盲剂量范围研究在一组同质的未经治疗的旋转性斜颈患者中进行,以获取剂量反应关系的客观数据。
75名患者被随机分配接受安慰剂治疗,或接受总剂量为250、500和1000单位的Dysport,分别注射到一侧头夹肌(0、175、350、700单位)和对侧胸锁乳突肌(0、75、150、300单位)。在基线以及治疗后第2、4和8周进行评估,包括改良的徐氏量表、四点疼痛量表、不良事件清单、改善情况的整体评估以及综合疗效和不良事件的整体评分。在第8周评估再次治疗的必要性,然后揭盲。对于仍有反应的患者,进行开放随访直至再次治疗,以评估疗效持续时间。
79%的患者在一次或多次随访中报告主观症状改善。500和1000单位组在第4周时改良徐氏评分较安慰剂组显著降低(p<0.05)。此外,在主观改善程度、改善持续时间、临床整体评分改善情况以及第8周再次注射的必要性方面发现了正剂量反应关系。在总体不良事件数量以及颈部肌肉无力和声音改变的发生率方面也建立了显著的剂量关系。
注射1000单位Dysport后改善程度和持续时间最大;然而,代价是不良事件显著增多。因此,建议颈部肌张力障碍患者起始剂量为500单位Dysport,如有临床必要,在后续注射时可向上滴定剂量。